Abstract The aim of this study was to evaluate the clinical value of assessing epidermal growth factor receptor (EGFR) amplification and the common 5′ rearrangement of EGFR resulting in the EGFRvIII transcript in astrocytic gliomas. Data from 221 tumours were correlated with patient survival. The majority of previous studies evaluated amplification alone and provided contradictory results. Amplification was analysed by a densitometry of Southern blot analysis or quantitative polymerase chain reaction (PCR). EGFR transcripts were examined by reverse transcription PCR and subsequent sequencing. A ribonuclease (RNase) protection assay was carried out on a subgroup to confirm PCR results. Amplification of EGFR was found in 41% (65/160) of glioblastomas (GBs) and 10% (4/41) of anaplastic astrocytomas (AAs). The EGFRvIII rearrangement was identified in 54% (35/65) of GBs and 75% (3/4) of AAs with amplification, as well as in 8% (8/95) of GBs and 5% (2/37) of AAs without amplification (confirmed by RNase protection assay). There were no abnormalities of the EFGR or its transcript in grade II astrocytoma (AII). We found no significant association between EGFR amplification or rearrangement, and age or survival in the 160 GB patients. We noted a tendency towards decreased survival with any EGFR abnormality in the 41 patients with AAs. This was most marked in the five cases with the EGFRvIII transcript (p=0.069), but these were significantly older than those without (p=0.023). No abnormalities of EGFR were identified in AII patients. We conclude that neither EGFR amplification nor the presence of the EGFRvIII transcript predicts patient outcome in conventionally treated GBs. However, in AAs, although uncommon, EGFR aberrations appear to be associated with shorter survival.
Introduction
The normal epidermal growth factor receptor (EGFR) gene on 7p codes for a 170-kDa transmembrane glycoprotein expressed in a variety of normal and malignant cells. It is composed of an N-terminal extracellular ligand-binding domain, a hydrophobic transmembrane region, a cytoplasmic part with intrinsic tyrosine kinase activity and a carboxy-terminal region with tyrosine residues and regulatory motifs [1] . At least six ligands for the EGFR are known [2] . When activated, wild-type EGFR forms homodimers or heterodimers (with other members of the erbB receptor family), triggering a number of signalling cascades via the Ras-mitogen-activated protein kinase pathway and the phosphatidyl-inositol 3′ kinase-protein kinase B (Akt) pathway [1] .
EGFR signalling is abnormal in a variety of tumour types, both of epithelial and neuroepithelial origin. In addition to amplification and/or overexpression, the amplified EGFR gene is frequently rearranged in glioblastomas (GBs) [3] [4] [5] [6] . Numerous different rearrangements have been reported, the most common being the 140-to 155-kDa EGFRvIII-a well-characterized and constitutively active variant with an in-frame deletion involving exons 2-7 [6] [7] [8] .
Among astrocytic tumours, aberrations of EGFR are most common in GBs (World Health Organization [WHO] classification, grade IV) and particularly so in "primary" (or de novo) GBs [9] [10] [11] . A small fraction (up to 18%) of anaplastic astrocytomas (AAs; WHO classification, grade III) also has EGFR amplification, while amplification in WHO classification, grade II astrocytomas (AII) has only been reported in single cases [12, 13] . GBs are the most frequent and most malignant human primary brain tumours in adults [14] . In GBs, EGFR is amplified in 30-40% [15, 16] and rearranged in up to approximately 20%, generally in combination with amplification [3, 17] . Attempts to correlate EGFR amplification analysis alone with outcome in GB and/or AA patients treated with conventional therapy (i.e. gross total surgical resection followed by external beam radiation therapy) have to date provided inconclusive or contradictory results [9, 10, 12, 13, [18] [19] [20] .
Here we have analysed the EGFR gene both for amplification and a common EGFRvIII rearrangement in a series of 221 astrocytic gliomas. The molecular findings have been correlated with survival to assess whether knowledge of these factors currently provides information that is of any value to clinicians. We show that with conventional therapy, the EGFR gene status and its transcripts are of little clinical value in cases of bona fide GBs. However, in AAs, the presence of EGFR amplification and/ or rearrangement may indicate shorter survival. The ongoing development of novel therapies targeting tyrosine kinase receptors, or specifically EGFRvIII, may make this analysis essential in selecting patients for such treatments.
Materials and methods
Tumour samples and DNA/RNA extraction A total of 221 patients with "primary", non-recurrent astrocytic tumours operated on at the Karolinska Hospital (Stockholm, Sweden) or Sahlgrenska University Hospital (Gothenburg, Sweden) between 1988 and 1997 were included in the study. In 10 cases, a tumour from two operations was available. All tumours were extensively sampled for histology and reassessed according to the histological criteria of the 2000 WHO classification [14] as 160 GBs, 41 AAs, and 20 astrocytomas (AII). No mixed gliomas or tumours with an oligodendroglioma component were included. We have reviewed the Swedish Cancer Register data for the two regions from which the tumour material was collected and found that, in both cases, about 20% of patients who received a GB diagnosis during the period of collection were included in this study. The mean age was slightly lower than the mean for all cases in the cancer registry, as resection was necessary for inclusion.
Patients not treated by gross total resection due to higher age and/or complicating diseases could not be included. Data on the irradiation treatment details of 30 GB and nine AA patients were not retrievable at review. The end of follow-up of the patients was set on October 1, 2003, providing a minimum follow-up time of 8.9 years of patients alive on that date. Clinical data were collected from patient records in the hospitals where they were treated and/or followed up. The data included the age and sex of the patient, tumour localization, duration and type of symptoms before diagnosis, date of operation(s), postoperative radiotherapy and date of death. All operations were gross total; thus, no cases diagnosed on biopsy alone were included. All patients gave informed consent, and ethics committee approval for the project was obtained at all sites.
The paired tumour and blood samples were stored at −135 or −80°C for up to 5 years before DNA extraction and, in the case of tumour tissues, RNA extraction. The majority of the tumours were included in previous studies, and each tumour piece analysed had, as assessed by histology, a minimum tumour cell content of 75% but generally greater than 90% tumour cells. The DNA and RNA from the tumour pieces and the DNA from the patients' peripheral blood were extracted as described previously [21] .
Gene copy number analysis: Southern blot analysis and quantitative polymerase chain reaction Southern blot analysis Five micrograms of 199 paired tumour and blood DNA was digested by the restriction enzyme TaqI, run into a 1% agarose gel and transferred to Hybond N + membranes. Hybridization, using the pEP1 probe (genomic; approximately 3 kb, 1 kb upstream and 2 kb downstream of exon 1, which includes only intron 1 sequences) and a cDNA probe from the 3′ non-coding re-gion produced by a reverse transcription polymerase chain reaction (RT-PCR) amplification of bases 3901-4010 (Gene Bank, X00588), as well as a PhosphorImager analysis, was performed as described previously [16, 22] . Probes that detected the highly informative polymorphic locus D2S44 (pYNH24) were used as a control locus. Amplification was assessed by measuring the hybridization signals using an ImageQuant software and by comparing the signals from the control locus and EGFR as described [22] .
Quantitative PCR determines gene copy number A realtime quantitative PCR of tumour DNA using LightCycler (Roche) and SYBR Green I (Roche Molecular Biochemicals or Sigma) was performed on 22 tumours to determine the presence of amplification where there was limited DNA. PCR products of the wild-type EGFR gene were used in a dilution series to establish standard curves. In each reaction, 1 ng of genomic DNA from each sample was used to determine the EGFR copy number. Each assay was done in duplicate. The final analysis was performed using a RelQuant (Roche) software. The EGFR region used for this quantitative PCR corresponded to 110 bases of exon 28 (which conferred to bases 3901-4010 of the wild-type transcript) and was located at the 3′ non-coding region. The control locus used here was WI-3360 and was located adjacent to the VNTR probe D2S44 used in assessing amplification on Southern blot analyses (see above).
cDNA analysis
Generation of cDNA The total RNA from each tumour sample was treated with 2 μl of ribonuclease (RNase)-free DNase I (Invitrogen) at 37°C for 30 min followed by Phenol/Chloroform/Isoamyl-alcohol to remove DNase I. The DNA-free RNA phase was precipitated and dissolved in RNasin/H 2 O and used to generate 100 μl of cDNA as follows. Three micrograms of total RNA was mixed with 6 μl of random primer pdn6 (10 ng/μl) in a 20-μl volume.
The mixture was denatured at 72°C for 10 min and cooled on ice immediately for 5 min. Five microlitres of DTT (100 mM), 5 μl of dNTP (10 mM), and 20 μl of 5× firststrand cDNA synthesis buffer were added up to a volume of 99 μl. This was then prewarmed at 37°C for 2 min, 1 μl of Superscriptase III (Invitrogen; 200 U/μl) was added and the solution was mixed and incubated at 45°C for 2 h. Then 1 μl of RNase H was added to each cDNA sample and incubated at 37°C for 15-30 min.
Standard PCR The PCR conditions for most experiments, except the discriminative PCR, have been described previously [21] . In brief, a 10-min predenaturation at 94°C was followed by 35 cycles of 94°C for 30 s-55°C for 30 s-72°C for 1 min, with a final extension at 72°C for 10 min, using standard buffers and MgCl 2 concentration. The positions of the primers used and the sequence details are shown in Fig. 1 .
Discriminative PCR differentiates wild-type transcript from EGFRvIII transcript The forward primer used in the discriminative PCR was PC66, which was located in exon 1 and was the same as the forward primer used to examine the 5′ end of the EGFR transcript; the reverse primer PC1445 was designed so that the first two bases were complimentary to the last two bases of exon 1 (bases 274-275), followed by a further 20 bases complimentary to the first 20 bases of exon 8 (bases 1076-1095). The template consisted of 1 μl of cDNA solution. The PCR conditions were 10 min of denaturation at 94°C, followed by 35 cycles of 94°C for 30 s-61°C for 30 s-72°C for 1 min and, finally, extension at 72°C for 10 min.
RNase protection assay A cDNA fragment of bases 177-628 of the wild-type EGFR transcript was generated with PC66/PC1855 by PCR. The reverse primer PC1855 had a T3 promoter sequence attached at its 5′ end, and the product was cloned into pBluescript II KS (−). A radioactive complimentary RNA probe was produced using the T7 promoter and T7 reverse transcriptase incorporating P-dCTP, as recommended in the Ambion Instruction Manual for MAXIscript In Vitro Transcription Kit. RNase protection assay (RPA) was also performed according to these recommendations. In brief, 500 pg of 32 P-labelled probe was mixed with 25 μg of total tumour RNA, ammonium acetate was added to a final concentration of 0.5 M and the mixture of total tumour RNA and probe was precipitated with ethanol. The pellets were resuspended in 10 μl of hybridization solution from the kit, and 1 μl of 1% sodium dodecyl sulphate was added. The mixture was incubated at 94°C for 3 min and then transferred to 42°C overnight. Two microlitres of RNase A/RNase T1 and 198 μl of RNase Digestion III buffer were mixed, 150 μl of this mixture was added to each sample and then this mixture was incubated at 37°C for 30 min. The RNase digestion was terminated by adding 225 μl of the Inactivation/Precipitation III solution. After precipitation, RNA pellets were dissolved in RNA sample loading buffer and run into 5% acrylamide/8 M urea gel. The gels were dried and exposed to phosphor screens, scanned in a PhosphorImager and analysed using the ImageQuant software as described [16, 22] .
Statistical analysis
All genetic data were categorized as either "normal" or "abnormal". For EGFR gene amplification, a minimum average EGFR gene copy number of seven per genome was categorized as "abnormal"; if the average copy number was less, the tumour was categorized as "normal". If the aberrant transcript EGFRvIII was present, the tumour was categorized as "abnormal". Absence of the EGFRvIII transcript was classified as "normal". Other rearrangements or combinations of rearrangements were not considered. The genetic data were complete except for EGFRvIII data on four GBs due to too little amount of RNA available.
The starting point for patient follow-up was the date of the first operation, with survival being reckoned from this date. All 160 GBs and 41 AAs were included in the survival analyses. Due to the absence of EGFR aberrations and the fact that median survival was not reached, the AII patients were not included in the survival analysis.
For a univariate analysis of single clinical or genetic factors and postoperative survival, the Wilcoxon-Gehan statistic [23] was performed. When a p value <0.100 was seen in the univariate analysis, a Cox regression analysis adjusting for age was performed. A stratification of GB patients (irradiated and non-irradiated, respectively) was done for subgroup analysis to explore if EGFR status could be associated with survival within a group of patients untreated after the operation, or be a predictor of outcome after postoperative radiotherapy. When analysing age and survival, with age as a continuous variable, Cox regression analysis was used. Comparing the age distribution of patients with or without EGFR abnormalities was done with an analysis of variance. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences), release 12.0.1.
Results

Clinical data
In Table 1a and b, the clinical data of all GB and AA cases are summarized, with median survival and some statistical comparisons. For the 160 GB patients, the median postoperative survival was 9.2 months and the mean age was 53.4 years. Only two GB patients were alive at the end of follow-up. Age and postoperative irradiation were the only clinical factors that showed significant survival differences. Age, analysed both as a continuous variable and as a dichotomous variable, was inversely associated with survival (p<0.001). GB patients given postoperative irradiation survived significantly longer than those not irradiated (p<0.001). In the bivariate analysis using Cox regression, both lower patient age and radiotherapy were found to be independently associated with survival (both p<0.001; Table 1a ).
The median survival of the 41 AA patients was 4.6 years and the mean age was 43.2 years. Twelve patients were alive at the end of follow-up. As was found in the case of GBs, patient age was inversely associated with survival. The AA patients given radiotherapy postoperatively had a longer median survival than those not irradiated, but this difference was not statistically significant.
Amplification: incidence and degree
Tumours with an average EGFR gene copy number of seven or more per genome were considered to have an amplification of the gene. Amplification was found in 65 of 160 GBs (41%). None of the 20 AIIs showed amplification, while four of 41 (9.8%) of the AAs did. The mean copy number in the amplified GBs was 44 copies (ranging from an average of eight to 151 copies per genome).
Ten patients were reoperated on. One AII progressed to an AA and one AA progressed to a GB. There was no evidence of amplification in either case. Eight GBs were reoperated on, five showed no evidence of amplification at either operation while two retained an amplified EGFR gene at the second operation. One GB had amplification only at the second operation. On reoperation, another patient with a GB with EGFR amplification on the first operation had a tumour that was histologically classified as an AA but retained the EGFR amplification. Representative cases of EGFR gene amplification status are shown in Fig. 2a .
Identifying wild-type and EGFRvIII transcripts
EGFRvIII is the most common aberrant EGFR form (found in up to 20% of GBs). While other aberrant forms exist, with either the extracellular or the cytoplasmic domain affected, they have only been documented in a single case or in very few cases. Using the primer pair PC66 and PC445 (Fig. 1) , the presence of the wild-type EGFR transcripts was demonstrated in all 221 cases. When primer PC66 was paired with PC1403 (corresponding to bases 1093-1076), one band representing the wild-type transcript (923 bp) was identified in all samples, whereas the EGFRvIII transcript (122 bp) was identified only in some tumours (Fig. 2a-c) .
In order to specifically identify even small amounts of the EGFRvIII transcript, a discriminative RT-PCR was designed using the PC66 primer paired with a primer (PC1445), with its two most 3′ bases complementary to the last two bases in exon 1 (bases 275 and 274) and the remaining 20 bases complementary to the first 20 bases in exon 8. This PCR, being specific for the EGFRvIII transcript, confirmed the previous findings, and 34 GBs and three AAs with EGFR amplification showed a corresponding 125-bp band (GB13 in Fig. 2c and d) . In addition, eight GBs and two AAs, which did not fulfil our criteria of EGFR amplification, showed the 125-bp band by RT-PCR using the primers PC66 and PC1403, indicating that these tumours also produced the transcript for EGFRvIII. All AIIs showed only a wild-type transcript product of 923 bp (using the primer pair PC66 and PC1403). The results from representative cases are shown in Fig. 2c and d .
An RPA was carried out in six cases where sufficient RNA was allowed to confirm the PCR findings where the EGFRvIII transcript was identified, including tumours that did not fulfil the criteria for the amplification of the gene (more than five copies). As described in Materials and methods, a 605-base complement RNA molecule was produced to protect the wild-type and EGFRvIII transcripts, resulting in the protection of a 458-base RNA sequence in the case of the wild-type transcript and a shorter 252-base sequence in the case of the EGFRvIII transcript (Fig. 3) . The findings confirmed the PCR analysis in all the six cases studied. A GB xenograft known to highly express the EGFRvIII transcript was used as a positive control (Fig. 3) .
In total, 42 GBs and five AAs expressed the EGFRvIII transcript. Of these, 34/42 GBs (81%) and 3/5 AAs (60%) also fulfilled the criteria for EGFR amplification, while 29/63 (two missing EGFRvIII data due to lack of RNA) GBs (46%) and 1/4 AAs (25%) with EGFR amplification showed no evidence of the EGFRvIII transcript.
EGFR gene abnormalities and survival: univariate and multivariate analyses
In the 160 GB patients, we found no significant associations between EGFR abnormalities (EGFR amplification and expression of the EGFRvIII transcript, respectively) and survival (Table 2a-c ). This was also tested in the subgroups of irradiated and non-irradiated GB patients, with no significant association with survival found. We also performed a univariate analysis by setting up three groups of patients with the presence of: (1) neither EGFRvIII nor EGFR amplification; (2) either EGFRvIII or EGFR amplification; and (3) both EGFRvIII and EGFR amplification. In the univariate analysis, none of these combinations provided any significant associations with survival (Table 3a-c).
In the 41 AAs, we found a tendency towards decreased survival times in the relatively few patients whose tumours had EGFR abnormalities. The five AAs expressing the EGFRvIII transcript, of which three also fulfilled the criteria of EGFR amplification, had a median survival of 1.3 years compared to 5.6 years in the 36 cases not expressing EGFRvIII (p=0.069). None of the survival differences regarding the AAs was statistically significant in bivariate analyses adjusting for age (Tables 2d and 3d ).
EGFR gene abnormalities and age
In the 160 GB patients, we found no significant associations between EGFR abnormalities and patient age (Table 4a and b). The AA patients with tumours with EGFR abnormalities had a higher mean age than those without. The age difference for AA cases with or without EGFRvIII was statistically significant (p=0.023) (Table 4c ). 
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+ -+ + Fig. 3 RPA demonstrating the presence of both the wild-type and the EGFRvIII transcript. A813 is the fourth passage of the xenograft with an amplified and rearranged EGFR gene, which mainly expresses the EGFRvIII transcript. GB182 is a GB without an amplification of the EGFR gene but expresses the EGFRvIII transcript, as is demonstrated here. GB180 and AA108 are tumours with EGFR amplification that only express the wild-type transcript
Discussion
The incidence of EGFR amplification in "primary" GBs (41%) and AAs (9.8%) was in accordance with earlier reports [10, 15, 18, 19] . The relative amounts of wild-type and EGFRvIII transcripts varied from case to case, as reported previously [3, 18] . In many tumours, there was only wild-type transcript, whereas in others, EGFRvIII or wildtype transcripts predominated. Many of the tumours required discriminative PCR for the demonstration of the EGFRvIII transcript, indicating that the levels of its expression can be very low in some cases. This may well be related to the number of wild-type or mutated EGFR gene copies that are present [24] . There has been some discussion in the literature on whether the EGFRvIII transcript occurs in the absence of amplification. The number of cases of astrocytic gliomas reported without amplification but expressing the EGFRvIII has been small. To exclude the possibility that the finding is a PCR artefact and that the EGFRvIII transcript truly exists in the absence of amplification, the RPA was performed in four of the tumours without amplification and with an RT-PCR product indicative of the EGFRvIII transcript. The findings confirmed the presence of the EGFRvIII transcript. The EGFR gene has yet to be examined in detail in these cases to see if the EGFR copies present show gene rearrangements or other kinds of mutations, or whether the EGFRvIII transcript is the result of an aberrant splicing of a wild-type gene, even [20] underscores this. The most recent and, to date, largest study on GB genetics and prognosis shows, as does our study, no association between survival and EGFR amplification [19] . However, the presence or absence of transcript abnormalities was not reported.
In one recent study on 87 GB patients that did attempt to document both EGFR amplification and EGFRvIII (as detected by immunohistochemistry), the data showed a relatively small but statistically significant survival difference (1.2 years compared to 1.7 years) in both univariate and bivariate analyses adjusting for age in favour of patients without amplification. A further division of the amplified group revealed an association between EGFRvIII expression and even shorter median survival [18] . In this study, patients from different randomized treatment studies were included, and some patients were only biopsied, which was a potential bias. In our study, no combination of EGFR amplification and presence of the EGFRvIII transcript in GBs was found to be associated with a good or a bad prognosis. However, our material was limited to craniotomy cases.
To explore if EGFR status could be associated with survival within a group of patients untreated after the operation or be a predictor of outcome after postoperative radiotherapy, subgroup analysis was performed, but without significant findings. Thus, from this and previous studies, it is reasonable to conclude that analysis of EGFR amplification and/or the presence of EGFRvIII is not a strong prognostic or predictive factor in conventionally treated GBs.
The difference in outcome between AA patients with or without EGFR amplification and EGFRvIII, respectively, was, however, more striking. All five patients with EGFRvIII had died before the end of follow-up, with a median survival of 1.3 years (compared to 5.6 years for AA patients with the absence of EGFRvIII). Such a short survival is closer to what might be expected in a series of GBs, rather than a series of AAs. This indicates that there exists a fraction of AA patients whose tumours lack the histological characteristics of a GB yet have a tumour form that shows an aggressive biological behaviour similar to that of GB, and that these cases may be identified by this kind of genetic analysis. The fact that the survival difference was not statistically significant in multivariate analysis probably reflects the small number of AAs studied. In a recent study of EGFRvIII with immunohistochemical techniques, EGFRvIII positivity was found to be associated with a poor outcome in AA patients in a univariate analysis, while no such association was found in GB patients [25] . They also found EGFRvIII positivity to be associated with higher age in the AA group, an association not found in the GB group. The study by Shinojima et al. [18] also presented data indicating the association of particular EGFR abnormalities and patient age. As presented in Table 4a -c, in our series of GB patients, we found no such associations, but the AA patients with EGFR abnormalities were older than those without.
During the last two decades, an awareness of the high frequency of genetic alterations and/or overexpression of EGFR in GBs and other tumour forms has led to the development of different treatment strategies targeting EGFR. These include passive immunotherapy using monoclonal antibodies against wild-type EGFR and/or the EGFRvIII variant [26] [27] [28] [29] , radioimmunotherapy [30] , small molecule tyrosine kinase inhibitors [31, 32] and radiolabelled or toxin-conjugated EGFR ligands [33, 34] . In order to choose the most optimal therapy from these new developments for individual patients, one will have to consider the affinity and specificity of the molecular therapy for the patients' tumour cells. Thus, the use of EGFR targeting therapies in clinical practice will require an analysis of the EGFR copy number, EGFR expression level, possible rearrangements and point mutations, resulting in aberrant transcripts and proteins. While the present findings indicate that a molecular analysis of the EGFR gene is of little prognostic value in conventional therapy, at least in the case of AII of GBs, it may become essential for adequate treatment decisions regarding novel molecular targeted therapies in the near future.
